Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea

Launched by INTEGRATIVE SKIN SCIENCE AND RESEARCH · Oct 2, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a special oral supplement containing L-histidine and antioxidants may improve skin health and reduce inflammation in people with rosacea, a skin condition that causes redness and bumps. The study aims to find out if taking this supplement can help strengthen the skin and gut barriers, which may lead to less inflammation and better management of rosacea symptoms.

To participate in this trial, individuals should be between 30 to 70 years old and have mild to moderate rosacea. Participants will need to stop using certain medications and supplements before joining the study. If eligible, participants can expect to take the supplement for a set period while keeping their skincare routine the same. This trial is currently recruiting volunteers, and it is important for potential participants to be aware of the specific requirements and restrictions before signing up.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and females 30 to 70 years of age
• • The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
• • High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L
• Exclusion Criteria:
• • The presence of severe rosacea as noted by the investigator global assessment.
• • Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
• • Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
• • Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.
• • Those who are unwilling to keep their facial regimen the same throughout the study.
• • Individuals who have been on an oral antibiotic within the previous one month.
• • Individuals who are pregnant or breastfeeding.
• • Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.
• • Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.
• • Use of isotretinoin within the three months prior to enrollment.
• • Individuals on finasteride or dutasteride
• • Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.